Functionalized bosutinib liposomes for target specific delivery in management of estrogen-positive cancer

Singh, Priya; Singh, Neelu; Mishra, Nidhi; Nisha, Raquibun; Alka,; Maurya, Priyanka; Pal, Ravi Raj; Singh, Samipta; Saraf, Shubhini A.

doi:10.1016/j.colsurfb.2022.112763

Cited by 9 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The candidate compounds screened from CMap were further selected based on their efficacy in inhibiting BRCA cell growth measured with IC 50 and EC 50 . Among the six identified drugs, bosutinib is a small molecule functioning as a dual inhibitor of BCR-ABL and Src tyrosine kinase for treating chronic myeloid leukemia (CML) and advanced solid tumors [ 72 ], including estrogen-positive breast cancer [ 73 ]. Dasatinib is an oral inhibitor of multiple tyrosine kinases, including BCR-ABL, Src, c-KIT, PDGFR-α, PDGFR-β, and ephrin receptor kinases [ 74 ].…”

Section: Discussionmentioning

confidence: 99%

Expression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer

Wang

Ducatman

et al. 2023

IJMS

View full text Add to dashboard Cite

There is currently no gene expression assay that can assess if premalignant lesions will develop into invasive breast cancer. This study sought to identify biomarkers for selecting patients with a high potential for developing invasive carcinoma in the breast with normal histology, benign lesions, or premalignant lesions. A set of 26-gene mRNA expression profiles were used to identify invasive ductal carcinomas from histologically normal tissue and benign lesions and to select those with a higher potential for future cancer development (ADHC) in the breast associated with atypical ductal hyperplasia (ADH). The expression-defined model achieved an overall accuracy of 94.05% (AUC = 0.96) in classifying invasive ductal carcinomas from histologically normal tissue and benign lesions (n = 185). This gene signature classified cancer development in ADH tissues with an overall accuracy of 100% (n = 8). The mRNA expression patterns of these 26 genes were validated using RT-PCR analyses of independent tissue samples (n = 77) and blood samples (n = 48). The protein expression of PBX2 and RAD52 assessed with immunohistochemistry were prognostic of breast cancer survival outcomes. This signature provided significant prognostic stratification in The Cancer Genome Atlas breast cancer patients (n = 1100), as well as basal-like and luminal A subtypes, and was associated with distinct immune infiltration and activities. The mRNA and protein expression of the 26 genes was associated with sensitivity or resistance to 18 NCCN-recommended drugs for treating breast cancer. Eleven genes had significant proliferative potential in CRISPR-Cas9/RNAi screening. Based on this gene expression signature, the VEGFR inhibitor ZM-306416 was discovered as a new drug for treating breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer

Wang

Ducatman

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…For instance, folate ligands target folate receptor [ 82 - 84 ] , transferrin ligands target transferrin receptor [ 85 , 86 ] , epidermal growth factor (EGF) protein [ 87 ] , epidermal growth factor receptor (EGFR) antibody [ 88 ] , and cetuximab [ 89 , 90 ] target EGFR, and prostate-specific peptide [ 91 ] and prostate-specific antigen gene [ 92 ] target prostate-specific membrane antigen (PSMA). Additionally, single-stranded DNA aptamer [ 93 ] targets forkhead box M1 (FOXM1), biotin [ 94 - 97 ] and fructose [ 96 ] target biotin receptor, and humanized anti-human epidermal growth factor receptor 2 (HER2) antibody [ 98 ] , engineered peptide [ 99 ] , and bispecific antibody [ 100 ] target HER2 receptor. Liposomes can also be designed for controlled release drug delivery to combat cancer drug resistance when exposed to physicochemical or biochemical stimuli, e.g., changes in pH [ 82 , 101 , 102 ] , specific enzymes [ 103 , 104 ] , ultrasound [ 105 , 106 ] , and so on.…”

Section: Lipid-based Nanomaterials For Cancer Resistancementioning

confidence: 99%

Recent advanced lipid-based nanomedicines for overcoming cancer resistance

Dechbumroong,

Hu,

Keaswejjareansuk

et al. 2024

Cancer Drug Resist

View full text Add to dashboard Cite

The increasing prevalence of cancer drug resistance not only critically limits the efficiency of traditional therapies but also causes relapses or recurrences of cancer. Consequently, there remains an urgent need to address the intricate landscape of drug resistance beyond traditional cancer therapies. Recently, nanotechnology has played an important role in the field of various drug delivery systems for the treatment of cancer, especially therapy-resistant cancer. Among advanced nanomedicine technologies, lipid-based nanomaterials have emerged as effective drug carriers for cancer treatment, significantly improving therapeutic effects. Due to their biocompatibility, simplicity of preparation, and potential for functionalization, lipid-based nanomaterials are considered powerful competitors for resistant cancer. In this review, an overview of lipid-based nanomaterials for addressing cancer resistance is discussed. We summarize the recent progress in overcoming drug resistance in cancer by these lipid-based nanomaterials, and highlight their potential in future applications to reverse cancer resistance.

show abstract

“…Singh et al. [51] designed and developed surface-functionalized bosutinib liposomes that exhibit estrogen-positive cancer activity via estrogen response elements, that contributes to the malignancy of cancer cells. DSPC-based liposomes were synthesized by activating the biotin carboxylic end using NHS and DCC.…”

Section: Functionalization Strategies For Immunoliposomesmentioning

confidence: 99%

“…DSPC-based liposomes were synthesized by activating the biotin carboxylic end using NHS and DCC. The activated biotin-NHS was then allowed to react with the amino-PEG-modified lipid surface (DSPC-PEG-NH 2 ) to form liposome derivatives that have been reported to be effective for targeted delivery [51] . Lian et al.…”

Section: Functionalization Strategies For Immunoliposomesmentioning

confidence: 99%

Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants

Mohammad Faizal,

Ramli,

Mat Rani

et al. 2023

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Functionalized bosutinib liposomes for target specific delivery in management of estrogen-positive cancer

Cited by 9 publications

References 49 publications

Expression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer

Expression-Based Diagnosis, Treatment Selection, and Drug Development for Breast Cancer

Recent advanced lipid-based nanomedicines for overcoming cancer resistance

Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants

Contact Info

Product

Resources

About